A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

California-based biotech Halozyme Therapeutics (Nasdaq: HALO) yesterday revealed it has filed a patent infringement lawsuit ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

Keytrda “still reigns” after the interim analysis for Akeso and Summit Therapeutics (SMMT)’ PD-1/VEGF “muddies the outlook” for a potential ivonescimab survival benefit in non-small cell lung cancer.

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial ...